Soleno Therapeutics (SLNO) Equity Average: 2014-2019
Historic Equity Average for Soleno Therapeutics (SLNO) over the last 5 years, with Sep 2019 value amounting to $14.4 million.
- Soleno Therapeutics' Equity Average fell 4.37% to $14.4 million in Q3 2019 from the same period last year, while for Sep 2019 it was $14.4 million, marking a year-over-year decrease of 4.37%. This contributed to the annual value of $28.6 million for FY2018, which is 89.18% up from last year.
- According to the latest figures from Q3 2019, Soleno Therapeutics' Equity Average is $14.4 million, which was down 23.34% from $18.7 million recorded in Q2 2019.
- In the past 5 years, Soleno Therapeutics' Equity Average registered a high of $28.4 million during Q2 2017, and its lowest value of -$11.2 million during Q1 2015.
- In the last 3 years, Soleno Therapeutics' Equity Average had a median value of $22.3 million in 2018 and averaged $21.5 million.
- Its Equity Average has fluctuated over the past 5 years, first skyrocketed by 573.05% in 2017, then plummeted by 39.79% in 2018.
- Soleno Therapeutics' Equity Average (Quarterly) stood at $966,408 in 2015, then surged by 373.26% to $4.6 million in 2016, then soared by 446.91% to $25.0 million in 2017, then fell by 10.81% to $22.3 million in 2018, then decreased by 4.37% to $14.4 million in 2019.
- Its last three reported values are $14.4 million in Q3 2019, $18.7 million for Q2 2019, and $27.0 million during Q1 2019.